Article Per Year (5 Year)
p-Index From 2020 - 2025
0.444
P-Index
This Author published in this journals
All Journal Jurnal Kefarmasian AKFARINDO Berkala Ilmiah Mahasiswa Farmasi
Alya Azzahra
Unknown Affiliation
Biochemistry, Genetics & Molecular Biology Chemistry Health Professions Immunology & microbiology Medicine & Pharmacology Social Sciences

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

 1 
Studi Penambatan Molekuler dan Prediksi ADMET Senyawa Bioaktif Beberapa Jamu Indonesia terhadap SARS-CoV-2 Main Protease (Mpro) Sheniez Adhitya Yasin; Alya Azzahra; Norman Emil Ramadhan; Vega Mylanda
Berkala Ilmiah Mahasiswa Farmasi Indonesia Vol 7 No 2 (2020): Berkala Ilmiah Mahasiswa Farmasi Indonesia (BIMFI)
Publisher : Ikatan Senat Mahasiswa Farmasi Seluruh Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.48177/bimfi.v7i2.45

Abstract

The novel coronavirus SARS-CoV-2 continues causing viral respiratory illness, known as Coronavirus Disease-2019 (COVID-19). COVID-19 is considered as the biggest global pandemic disease in 2020 and its antiviral therapies are still lacking worldwide. Current studies are still trying to find potential therapies of the disease, including from natural compounds. Therefore, it is important to acknowledge what the most effective herbs’ compounds can be used against the virus. Jamu is traditional medicine from herbs in Indonesia that possesses some medicinal properties. This research was done to find and explore the potential of Indonesian jamus as novel COVID-19 treatment. 283 bioactive compounds from Indonesian jamus were screened with ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity) predictions and Lipinski’s Rule of Five parameters using ProTox-II and SwissADME. The 12 screened compounds then continued to be tested through molecular docking against SARS-CoV-2 Main Protease (Mpro) using AutoDock Vina. The result of our study showed that Curcuminol D has the lowest binding free energy of -6.9 kcal/mol and Ki (inhibition constant) of 2.99 µM compared to the other screened compounds. However, none of the screened compounds has lower binding free energy than the positive controls’, which valued -8.2 kcal/mol (Lopinavir) and -7.8 kcal/mol (Ritonavir). Despite their unfulfilled parameters, the other 271 compounds might have higher potential than the standard drugs. Therefore, the finding in the present study can be used as a starting point in the drug discovery process from natural compounds for treating COVID-19.
BIAYA MEDIS LANGSUNG PADA PASIEN PENYAKIT GINJAL KRONIK DI RUMAH SAKIT PKU MUHAMMADIYAH BANTUL Alya Azzahra; Woro Supadmi
Jurnal Kefarmasian Akfarindo Vol 9 No 1 (2024)
Publisher : Akademi Farmasi Indonesia Yogyakarta

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37089/jofar.vi0.265

Abstract

Pembiayaan hemodialisis pada pasien penyakit ginjal kronik menjadi beban ekonomi. Berdasarkan hasil studi tahun 2021 pasien yang menjalani hemodialisis pada tahun 2020-2021 di RSU PKU Muhammadiyah Bantul berjumlah 172 orang. Tujuan penelitian ini untuk mengetahui biaya medis langsung pada pasien penyakit ginjal kronik dengan hemodialisis. Metode penelitian yang digunakan adalah observasional deskriptif dengan pengumpulan data retrospektif. Pasien yang diambil adalah pasien penyakit ginjal kronik dengan hemodialisis bulan Juni 2022 yang memenuhi kriteria inklusi. Data yang dikumpulkan meliputi karakteristik pasien, data pengobatan, data laboratorium dari rekam medik. Biaya perspektif rumah sakit dari biaya medis langsung yang diperoleh dari dari bagian ’keuangan. Data dianalisis secara deskriptif. Hasil penelitian diperoleh 93 sampel pasien penyakit ginjal kronik dengan hemodialisis yang melakukan rawat jalan. Terdapat 7 pasien yang mendapatkan obat, diantaranya furosemide, irbesartan, asam folat dan vipiron. Biaya pada pasien ginjal kronik di RSU PKU Muhammadiyah Bantul meliputi biaya pendaftaran Rp 11.000, biaya laboratorium Rp 72.000, dan biaya hemodialisis Rp 1.177.000. Terdapat 7 pasien yang menggunakan obat dengan rata-rata total biaya sebesar Rp1.396.484, sedangkan 86 pasien tanpa menggunakan obat dengan rata-rata total biaya sebesar Rp 1.260.000. Kesimpulan biaya medis langsung pada pasien penyakit ginjal kronik dengan hemodialisis di RSU PKU Muhammadiyah Bantul bulan Juni 2022 yang menggunakan obat adalah sebesar Rp 1.396.484, sedangkan pasien tanpa menggunakan obat sebesar Rp 1.260.000.
Co-Authors Norman Emil Ramadhan Sheniez Adhitya Yasin Vega Mylanda Woro Supadmi